ADD2 Gene Hypertension Genetic Test in UAE | 2800 AED | DHA Licensed

Name: ADD2 Gene Hypertension Genetic Test
Brand: DNA Labs UAE
SKU: DX-LAB-4035
Price: 2800 AED
Availability: InStock

Executive Summary & Core Metrics

This high‑precision genetic test uses next‑generation sequencing (NGS) to detect ADD2 gene variants associated with essential hypertension. It is paired with mandatory pre‑ and post‑test genetic counselling and follows DHA regulatory standards.

✓

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.

✦

Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection (8 AM – 11 PM) or hospital draw.

☏

Clinical Guidance: DHA‑licensed physician telephonic interpretation of results.

⚕

Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

What this test does: This advanced NGS assay examines the entire coding region of the ADD2 (adducin beta) gene, identifying germline variants strongly associated with primary (essential) hypertension susceptibility, salt‑sensitive blood pressure phenotypes, and early cardiovascular risk stratification.

Who prescribes it? General physicians, primary care doctors, and medical researchers. The test is designed for individuals with a family history of hypertension or those seeking proactive genomic wellness insights under professional supervision.

Parameter	Our ADD2 NGS Test	Standard Single‑Gene Sequencing
Methodology	NGS covering all exons ± splice sites, validated by LC‑MS/MS for variant confirmation	Sanger sequencing of selected exons only
Variant Detection	SNVs, indels, and copy number variants (CNVs) for comprehensive risk profiling	Limited to known hot‑spot mutations
Turnaround Time	3–4 weeks	6–8 weeks
Clinical Utility	Precision medicine guidance, family screening, personalised antihypertensive choice	Basic diagnostic confirmation only

Physician Insight & Safety Protocols

"The ADD2 gene plays a critical role in sodium transport and vascular tone. This NGS test gives us a powerful tool to personalise hypertension management. Remember, a genetic risk variant is not a diagnosis; it is an opportunity for early intervention. Always combine this result with your blood pressure trends, family history, and lifestyle factors for a complete picture."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA License: 9294403

Medication Advisory

⚠ Medication Warning

Do not discontinue any prescribed antihypertensive medication without consulting your physician. This test is for risk assessment, not acute management.

Exclusion Criteria & Emergency Red Flags

Patients unwilling or unable to provide informed consent after genetic counselling.
Minors without legal guardian consent, in compliance with UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Individuals with acute hypertensive emergency (systolic >180 mmHg or diastolic >120 mmHg with organ damage) – seek immediate ER care; this test is not for crisis diagnosis.
Severe headache, blurred vision, chest pain, shortness of breath, or confusion: proceed to nearest emergency department; genetic testing cannot replace urgent intervention.
Pregnancy is not an exclusion but requires specialised obstetric counselling per UAE data protection rules before testing.

Patient FAQ & Clinical Guidance

1. What does the ADD2 hypertension genetic test evaluate?

Direct Answer: The ADD2 NGS test identifies DNA variants in the adducin beta gene that increase your lifelong risk of developing essential hypertension. It analyses the full coding sequence for mutations that affect renal sodium handling and vascular tone, providing a genetic susceptibility profile that complements blood pressure monitoring and lifestyle assessment.

2. How accurate is the test and is it accepted by DHA?

Direct Answer: Our ISO 9001:2015‑accredited NGS platform achieves over 99.9% analytical sensitivity and specificity, fully recognised under DHA/MOHAP molecular diagnostics guidelines. The laboratory is licensed under DHA Facility License 1143 and follows rigorous quality control, including liquid chromatography‑mass spectrometry (LC‑MS/MS) confirmation for positive findings. All reports comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on health ICT use.

3. What preparation is needed before sample collection?

Direct Answer: You must complete a mandatory pre‑genetic counselling session to discuss your family history and sign informed consent before the blood draw. No fasting is required; however, provide a detailed clinical history of any hypertension diagnoses and current medications. Our coordinator will guide you through the consent process and arrange a VIP mobile phlebotomy at your home or workplace between 8 AM and 11 PM. The counselling ensures you understand the implications and complies with PDPL 2021 and Federal Law No. 2 of 2019.

UAE Regulatory & Data Privacy Adherence

Your data is protected. DNA Labs UAE operates under the full legal framework of the United Arab Emirates. All genetic and personal information is processed in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. This test is conducted under DHA Facility License 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.

Clinical & Logistical Metadata

Test Name	ADD2 Gene Hypertension Genetic Test (NGS)
Price (AED)	2,800
Turnaround Time	3–4 weeks
Sample Type / Matrix	Whole blood (peripheral) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection
Methodology Used	Next‑Generation Sequencing (NGS) with LC‑MS/MS variant confirmation
ICD‑10‑CM Code	I10
LOINC Code	48018-6
DHA Facility License & Address	License 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE